Study wrapper · #1024
Cost-Effectiveness of Endoscopic Bariatric Therapies Compared with Laparoscopic Sleeve Gastrectomy and Semaglutide.
Afentou N, Hall J, Okeke Ogwulu C, et al. Obesity surgery. 2026.
DOI: 10.1007/s11695-026-08854-4PubMed: 42484827
Editor's note
A health-economic modeling study evaluating obesity interventions from a UK National Health Service perspective, with semaglutide serving as the pharmacotherapy comparator. The findings concern cost-effectiveness rather than clinical efficacy or safety, and depend heavily on modeling assumptions about long-term weight regain. Useful context on how semaglutide compares economically with procedural options, but not a source of new clinical evidence.
Plain-language abstract
This UK cost-effectiveness analysis compared endoscopic weight-loss procedures with sleeve gastrectomy surgery and with semaglutide. Semaglutide was more cost-effective than an intragastric balloon but less so than endoscopic sleeve gastroplasty for lower-BMI patients.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026